Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Is there room for new non-dopaminergic treatments in Parkinson's disease?

Pilleri M, Koutsikos K, Antonini A.

J Neural Transm (Vienna). 2013 Feb;120(2):349-52. doi: 10.1007/s00702-012-0947-z. Epub 2012 Dec 11.

PMID:
23229903
2.

Is there room for non-dopaminergic treatment in Parkinson disease?

Lieberman A, Krishnamurthi N.

J Neural Transm (Vienna). 2013 Feb;120(2):347-8. doi: 10.1007/s00702-012-0946-0. Epub 2012 Dec 16.

PMID:
23242741
3.

Non-dopaminergic treatments for motor control in Parkinson's disease.

Fox SH.

Drugs. 2013 Sep;73(13):1405-15. doi: 10.1007/s40265-013-0105-4. Review. Erratum in: Drugs. 2014 Jul;74(11):1305.

PMID:
23917951
4.

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

Hung AY, Schwarzschild MA.

Neurotherapeutics. 2014 Jan;11(1):34-46. doi: 10.1007/s13311-013-0239-9. Review.

5.

New pharmacological options for treating advanced Parkinson's disease.

Devos D, Moreau C, Dujardin K, Cabantchik I, Defebvre L, Bordet R.

Clin Ther. 2013 Oct;35(10):1640-52. doi: 10.1016/j.clinthera.2013.08.011. Epub 2013 Sep 5. Review.

6.

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.

Lang AE, Obeso JA.

Lancet Neurol. 2004 May;3(5):309-16. Review.

PMID:
15099546
7.

New treatments for the motor symptoms of Parkinson's disease.

Vijverman AC, Fox SH.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):761-77. doi: 10.1586/17512433.2014.966812. Review.

PMID:
25318835
8.

Management of motor and non-motor symptoms in Parkinson's disease.

Sprenger F, Poewe W.

CNS Drugs. 2013 Apr;27(4):259-72. doi: 10.1007/s40263-013-0053-2. Review.

PMID:
23515972
9.

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Olanow CW, Obeso JA, Stocchi F.

Nat Clin Pract Neurol. 2006 Jul;2(7):382-92. Review.

PMID:
16932589
10.

Continuous drug delivery in Parkinson's disease.

Senek M, Nyholm D.

CNS Drugs. 2014 Jan;28(1):19-27. doi: 10.1007/s40263-013-0127-1. Review.

PMID:
24323838
11.

Rationale for current therapies in Parkinson's disease.

Romrell J, Fernandez HH, Okun MS.

Expert Opin Pharmacother. 2003 Oct;4(10):1747-61. Review.

PMID:
14521485
12.

Early Parkinson's disease: what is the best approach to treatment.

Hristova AH, Koller WC.

Drugs Aging. 2000 Sep;17(3):165-81. Review.

PMID:
11043817
13.
14.

Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.

Olanow CW.

Mov Disord. 2008;23 Suppl 3:S613-22. doi: 10.1002/mds.22061. Review.

PMID:
18781663
15.

[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].

Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L.

Rev Neurol (Paris). 2009 Aug-Sep;165(8-9):718-27. doi: 10.1016/j.neurol.2008.11.017. Epub 2009 Jan 15. French.

PMID:
19150100
16.

[Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].

Devos D, Bordet R, Defebvre L.

Rev Neurol (Paris). 2010 Feb;166(2):168-77. doi: 10.1016/j.neurol.2009.07.017. Epub 2009 Oct 6. Review. French.

PMID:
19811797
17.

Levodopa in Parkinson's disease: from the past to the future.

Pezzoli G, Zini M.

Expert Opin Pharmacother. 2010 Mar;11(4):627-35. doi: 10.1517/14656561003598919. Review.

PMID:
20163273
18.

Therapeutic prospects for Parkinson disease.

Olanow CW, Schapira AH.

Ann Neurol. 2013 Sep;74(3):337-47. doi: 10.1002/ana.24011. Review.

PMID:
24038341
19.

New and emerging medical therapies in Parkinson's disease.

Lotia M, Jankovic J.

Expert Opin Pharmacother. 2016;17(7):895-909. doi: 10.1517/14656566.2016.1149163. Epub 2016 Feb 19. Review.

PMID:
26830844
20.

Continuous dopaminergic stimulation achieved by duodenal levodopa infusion.

Odin P, Wolters E, Antonini A.

Neurol Sci. 2008 Dec;29 Suppl 5:S387-8. doi: 10.1007/s10072-008-1054-7.

PMID:
19381770

Supplemental Content

Support Center